Haleon (HLNCF) Net Income towards Common Stockholders (2021 - 2023)
Haleon (HLNCF) recorded quarterly Net Income towards Common Stockholders of $453.0 million in Q4 2023, up 21.48% on a QoQ basis from $372.9 million in Q2 2023, and up 11.95% year-over-year from $404.7 million in Q4 2022.
Haleon (HLNCF) Net Income towards Common Stockholders (2021 - 2023) Analysis & Trends
Haleon has disclosed Net Income towards Common Stockholders across 3 years of filings, most recently posting $453.0 million for Q4 2023.
- Quarterly Net Income towards Common Stockholders rose 11.95% year-over-year to $453.0 million in Q4 2023, while the trailing twelve-month figure through Dec 2025 was $453.0 million (down 45.15% YoY) and the FY2025 annual result came in at $2.2 billion, up 19.24% from the prior year.
- Net Income towards Common Stockholders climbed to $453.0 million in Q4 2023, from $372.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $1.5 billion in Q3 2022 and troughed at $372.9 million in Q2 2023.
- A 3-year average of $669.3 million and a median of $464.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 52.5% — and 2023, when it climbed 11.95%.
- Tracing HLNCF's Net Income towards Common Stockholders over 3 years: stood at $851.9 million in 2021, then sank by 52.5% to $404.7 million in 2022, then grew by 11.95% to $453.0 million in 2023.
- Business Quant data shows HLNCF's Net Income towards Common Stockholders at $453.0 million in Q4 2023, $372.9 million in Q2 2023, and $475.7 million in Q2 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Haleon | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 453.02 Mn |
| Jun 30, 2023 | 372.91 Mn |
| May 3, 2023 | 475.66 Mn |
| Dec 31, 2022 | 404.66 Mn |
| Sep 20, 2022 | 1.46 Bn |
| Dec 31, 2021 | 851.94 Mn |